Renal Cell Carcinoma: A Review
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Importance: Renal cell carcinoma (RCC) is a common malignancy, with an estimated 434 840 incident cases worldwide in 2022. In the US, it is the sixth most common cancer among males and ninth among females. Observations: Clear cell RCC is the most common histologic subtype (75%-80% of cases) and is characterized by inactivation of the von Hippel Lindau (VHL) tumor suppressor gene. Many patients (37%-61%) are diagnosed with RCC incidentally on an abdominal imaging study such as ultrasound or computed tomographic scan, and 70% of patients have stage I RCC at diagnosis. Although its incidence has increased approximately 1% per year from 2015 through 2019, the mortality rate of RCC has declined about 2% per year in the US from 2016 through 2020. Patients with a solid renal mass or complex cystic renal mass should be referred to urology. Treatment options for RCC confined to the kidney include surgical resection with partial or radical nephrectomy, ablative techniques (eg, cryoablation, radiofrequency ablation, radiation), or active surveillance for some patients (especially those with renal masses <2 cm). For patients with renal masses less than 4 cm in size (48% of patients), partial nephrectomy can result in a 5-year cancer-specific survival of more than 94%. For advanced or metastatic RCC, combinations of immune checkpoint inhibitors or the combination of immune checkpoint inhibitors with tyrosine kinase inhibitors are associated with tumor response of 42% to 71%, with a median overall survival of 46 to 56 months. Conclusions and Relevance: RCC is a common malignancy that is often diagnosed incidentally on an abdominal imaging study. Seventy percent of patients are diagnosed with stage I RCC and 11% of patients with stage IV. First-line treatments for early-stage RCC are partial or radical nephrectomy, which can result in 5-year cancer-specific survival of more than 94%, ablative techniques, or active surveillance. New treatment options for patients with metastatic RCC include immune checkpoint inhibitors and tyrosine kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Epidemiology of Renal Cell Carcinoma
Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., Gore, J. L., Sun, M., Wood, C., & Russo, P. (2019) · European Urology · doi:10.1016/j.eururo.2018.08.036 · Cited by 1,618
Huang, W. C., Levey, A. S., Serio, A. M., Snyder, M., Vickers, A. J., Raj, G. V., Scardino, P. T., & Russo, P. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70803-8 · Cited by 1,613
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bedke, J., Capitanio, U., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., Hora, M., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.03.006 · Cited by 1,508
Global burden of cancer attributable to high body-mass index in 2012: a population-based study
Arnold, M., Pandeya, N., Byrnes, G., Renehan, A. G., Stevens, G. A., Ezzati, M., Ferlay, J., Miranda, J. J., Romieu, I., Dikshit, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71123-4 · Cited by 997
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803675 · Cited by 946
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
Self-citation2004 WHO Classification of the Renal Tumors of the Adults
Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Kirkali, Z. (2006) · European Urology · doi:10.1016/j.eururo.2005.11.035 · Cited by 893
Moch, H., Amin, M. B., Berney, D. M., Compérat, E. M., Gill, A. J., Hartmann, A., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.06.016 · Cited by 846
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I
Campbell, S. C., Clark, P. E., Chang, S. S., Karam, J. A., Souter, L., & Uzzo, R. G. (2021) · Journal of Urology · doi:10.1097/ju.0000000000001911 · Cited by 775
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714
Obesity, Hypertension, and the Risk of Kidney Cancer in Men
Chow, W.-H., Gridley, G., Fraumeni, J. F., & Järvholm, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431804 · Cited by 668
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I. H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0001 · Cited by 667
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611
Self-citationMolecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Motzer, R. J., Banchereau, R., Hamidi, H., Powles, T., McDermott, D., Atkins, M. B., Escudier, B., Liu, L.-F., Leng, N., Abbas, A. R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.011 · Cited by 569
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001079 · Cited by 519
Pierorazio, P. M., Johnson, M. H., Ball, M. W., Gorin, M. A., Trock, B. J., Chang, P., Wagner, A. A., McKiernan, J. M., & Allaf, M. E. (2015) · European Urology · doi:10.1016/j.eururo.2015.02.001 · Cited by 396
Patel, H. D., Johnson, M. H., Pierorazio, P. M., Sozio, S. M., Sharma, R., Iyoha, E., Bass, E. B., & Allaf, M. E. (2016) · Journal of Urology · doi:10.1016/j.juro.2015.11.029 · Cited by 364
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y.-H., Lee, J.-L., Sarwar, N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312695 · Cited by 346
Dudani, S., de Velasco, G., Wells, J. C., Gan, C. L., Donskov, F., Porta, C., Fraccon, A., Pasini, F., Lee, J. L., Hansen, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.21869 · Cited by 312
Powles, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Gurney, H., Chang, Y.-H., Lee, J. L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00487-9 · Cited by 294
Pesch, B., Haerting, J., Ranft, U., Klimpel, A., Oelschlägel, B., & Schill, W. (2000) · International Journal of Epidemiology · doi:10.1093/ije/29.6.1014 · Cited by 292
An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma
Hakimi, A. A., Furberg, H., Zabor, E. C., Jacobsen, A., Schultz, N., Ciriello, G., Mikklineni, N., Fiegoli, B., Kim, P. H., Voss, M. H., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt310 · Cited by 290
Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthélémy, P., Plimack, E. R., Porta, C., George, S., et al. (2022) · Cancer · doi:10.1002/cncr.34180 · Cited by 261
Pal, S. K., Uzzo, R., Karam, J. A., Master, V. A., Donskov, F., Suarez, C., Albiges, L., Rini, B., Tomita, Y., Kann, A. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01658-0 · Cited by 253
Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis
KIM, H. L., BELLDEGRUN, A. S., FREITAS, D. G., BUI, M. H. T., HAN, K.-R., DOREY, F. J., & FIGLIN, R. A. (2003) · Journal of Urology · doi:10.1097/01.ju.0000092764.81308.6a · Cited by 217
Carlo, M. I., Mukherjee, S., Mandelker, D., Vijai, J., Kemel, Y., Zhang, L., Knezevic, A., Patil, S., Ceyhan-Birsoy, O., Huang, K.-C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1986 · Cited by 187
Vasudev, N. S., Wilson, M., Stewart, G. D., Adeyoju, A., Cartledge, J., Kimuli, M., Datta, S., Hanbury, D., Hrouda, D., Oades, G., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035938 · Cited by 177
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
Kaelin, W. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162480 · Cited by 161
Genetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 160
Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M., Gonzalez, R. C., Clark, J. I., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0522-3 · Cited by 156
Siva, S., Ali, M., Correa, R. J. M., Muacevic, A., Ponsky, L. E., Ellis, R. J., Lo, S. S.-M., Onishi, H., Swaminath, A., McLaughlin, M. F., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00656-8 · Cited by 152
Guðbjartsson, T., Thoroddsen, Á., Pétursdóttir, V., Harðarson, S., Magnússon, J., & Einarsson, G. (2005) · Urology · doi:10.1016/j.urology.2005.07.009 · Cited by 113
Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma
Al‐Ahmadie, H. A., Alden, D., Qin, L., et al. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181570343 · Cited by 103
Imaging in Suspected Renal-Cell Carcinoma: Systematic Review
Vogel, C., Ziegelmüller, B., Ljungberg, B., Bensalah, K., Bex, A., Canfield, S. E., Giles, R. H., Hora, M., Kuczyk, M. A., Merseburger, A. S., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.024 · Cited by 90
Palumbo, C., Pecoraro, A., Knipper, S., Rosiello, G., Luzzago, S., Deuker, M., Tian, Z., Shariat, S. F., Simeone, C., Briganti, A., et al. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.05.003 · Cited by 84
Kroeger, N., Choueiri, T. K., Lee, J.-L., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., Wood, L. A., Srinivas, S., Vaishamayan, U. N., Rha, S. Y., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.07.031 · Cited by 82
Ernst, M. S., Navani, V., Wells, J. C., Donskov, F. N., Basappa, N. S., Labaki, C., Pal, S. K., Meza, L., Wood, L. A., Ernst, D. S., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.01.001 · Cited by 82
Allaf, M., Kim, S. E., Harshman, L. C., McDermott, D. F., Master, V. A., Signoretti, S., Cole, S., Moon, H., Adra, N., Singer, E. A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.072 · Cited by 75
Regan, M. M., Jegede, O. A., Mantia, C. M., Powles, T. B., Werner, L. L., Motzer, R. J., Tannir, N. M., Lee, C., Tomita, Y., Voss, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2283 · Cited by 67
ACR Appropriateness Criteria Renal Cell Carcinoma Staging
Vikram, R., Beland, M. D., Blaufox, M. D., Moreno, C. C., Gore, J. L., Harvin, H. J., Heilbrun, M. E., Liauw, S. L., Nguyen, P. L., Nikolaidis, P., et al. (2016) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2016.01.021 · Cited by 49
Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A. S., Miletello, G. P., Curti, B. D., Agarwal, N., Hauke, R. J., Mahoney, K. M., Moon, H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0567-3 · Cited by 49
Reid, P. D., Cifu, A. S., & Bass, A. R. (2021) · JAMA · doi:10.1001/jama.2020.17308 · Cited by 46
Stage-specific conditional survival in renal cell carcinoma after nephrectomy
Cheaib, J., Patel, H. D., Johnson, M. H., Gorin, M. A., Haut, E. R., Canner, J. K., Allaf, M. E., & Pierorazio, P. M. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.08.011 · Cited by 43
Pallagani, L., Choudhary, G. R., Pandey, H., Madduri, V. K. S., Singh, M., Gupta, P., Shrivastava, N., Baid, G., Rao, M., Nalwa, A., et al. (2021) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.v8i1.154 · Cited by 40
Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study
Duarte, C., Hu, J., Beuselinck, B., Panian, J. A., Weise, N., Dizman, N., Collier, K. A., Rathi, N., Li, H., Elias, R. M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102018 · Cited by 32
Self-citationThe 2019 Nobel Prize honors fundamental discoveries in hypoxia response
Moslehi, J., & Rathmell, W. K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci134813 · Cited by 25
Jonasch, E. W., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S. M., Else, T., Maranchie, J. K., Welsh, S. J., Iversen, A. B. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4546 · Cited by 21
Yin, Q., Xu, H., Zhong, Y., Ni, J., & Hu, S. (2022) · BMC Cancer · doi:10.1186/s12885-022-09239-3 · Cited by 20
Research works printed but not linked: 28
- Jayson, 1998, Increased incidence of serendipitously discovered renal cell carcinoma., Urology, 51, 203, 10.1016/S0090-4295(97)00506-2 · doi:10.1016/s0090-4295(97)00506-2
- Cheung, 2016, Cancer incidence and mortality in chronic dialysis population: a multicenter cohort study., Am J Nephrol, 43, 153, 10.1159/000445362 · doi:10.1159/000445362
- Henschler, 1995, Increased incidence of renal cell tumors in a cohort of cardboard workers exposed to trichloroethene., Arch Toxicol, 69, 291, 10.1007/s002040050173 · doi:10.1007/s002040050173
- Skinner, 1971, Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases., Cancer, 28, 1165, 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G · doi:10.1002/1097-0142(1971)28:5<1165::aid-cncr2820280513>3.0.co;2-g
- Takeuchi, 2021, Cancer prevalence and risk stratification in adults presenting with hematuria: a population-based cohort study., Mayo Clin Proc Innov Qual Outcomes, 5, 308, 10.1016/j.mayocpiqo.2020.12.001 · doi:10.1016/j.mayocpiqo.2020.12.001
- Loughlin, 2023, The great masquerader’s new wardrobe in the modern era: the paraneoplastic manifestations of renal cancer., Urol Clin North Am, 50, 305, 10.1016/j.ucl.2023.01.005 · doi:10.1016/j.ucl.2023.01.005
- Moldovan, 2023, Incidence and clinical relevance of paraneoplastic syndromes in patients with renal cell carcinoma., Urol Oncol, 41, 392.e11, 10.1016/j.urolonc.2023.06.015 · doi:10.1016/j.urolonc.2023.06.015
- Hegemann, 2018, Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma., World J Urol, 36, 849, 10.1007/s00345-018-2215-9 · doi:10.1007/s00345-018-2215-9
- Herts, 2018, Management of the incidental renal mass on CT: a white paper of the ACR Incidental Findings Committee., J Am Coll Radiol, 15, 264, 10.1016/j.jacr.2017.04.028 · doi:10.1016/j.jacr.2017.04.028
- Patel, 2019, Clinical stage migration and survival for renal cell carcinoma in the United States., Eur Urol Oncol, 2, 343, 10.1016/j.euo.2018.08.023 · doi:10.1016/j.euo.2018.08.023
- Ficarra, 2002, Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases., Eur Urol, 41, 190, 10.1016/S0302-2838(01)00027-6 · doi:10.1016/s0302-2838(01)00027-6
- Dagher, 2017, Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading., Histopathology, 71, 918, 10.1111/his.13311 · doi:10.1111/his.13311
- Johnson, 2015, Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate., J Urol, 193, 30, 10.1016/j.juro.2014.07.102 · doi:10.1016/j.juro.2014.07.102
- Rais-Bahrami, 2009, Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention., BJU Int, 103, 1355, 10.1111/j.1464-410X.2008.08242.x · doi:10.1111/j.1464-410x.2008.08242.x
- Cheung, 2023, A matched analysis of active surveillance versus nephrectomy for T1a small renal masses., Eur Urol Oncol, 6, 535, 10.1016/j.euo.2023.01.008 · doi:10.1016/j.euo.2023.01.008
- Ozambela, 2020, Contemporary trends in percutaneous renal mass biopsy utilization in the United States., Urol Oncol, 38, 835, 10.1016/j.urolonc.2020.07.022 · doi:10.1016/j.urolonc.2020.07.022
- Srivastava, 2021, Renal mass biopsy: a strategy to reduce associated costs and morbidity when managing localized renal masses., Urol Oncol, 39, 790.e9, 10.1016/j.urolonc.2021.06.015 · doi:10.1016/j.urolonc.2021.06.015
- Asselin, 2020, Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?, Urol Oncol, 38, 798.e9, 10.1016/j.urolonc.2020.06.001 · doi:10.1016/j.urolonc.2020.06.001
- Pierorazio, 2016, Management of renal masses and localized renal cancer: systematic review and meta-analysis., J Urol, 196, 989, 10.1016/j.juro.2016.04.081 · doi:10.1016/j.juro.2016.04.081
- Neves, 1987, Surgical treatment of renal cancer with vena cava extension., Br J Urol, 59, 390, 10.1111/j.1464-410X.1987.tb04832.x · doi:10.1111/j.1464-410x.1987.tb04832.x
- Ciancio, 2010, Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience., Eur Urol, 57, 667, 10.1016/j.eururo.2009.06.009 · doi:10.1016/j.eururo.2009.06.009
- Pecoraro, 2019, Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer., J Urol, 202, 1120, 10.1097/JU.0000000000000460 · doi:10.1097/ju.0000000000000460
- Motzer, 2024, Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from part B of the randomized, phase 3 CheckMate 914 trial., J Clin Oncol, 42, LBA358, 10.1200/JCO.2024.42.4_suppl.LBA358 · doi:10.1200/jco.2024.42.4_suppl.lba358
- Wang, 2023, Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan., J Clin Oncol, 41, 733, 10.1200/JCO.2023.41.6_suppl.733 · doi:10.1200/jco.2023.41.6_suppl.733
- Appleman, 2024, Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease after metastasectomy: ECOG-ACRIN E2810., J Clin Oncol, 42, 2061, 10.1200/JCO.23.01544 · doi:10.1200/jco.23.01544
- Tannir, 2024, Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial., J Clin Oncol, 42, 363, 10.1200/JCO.2024.42.4_suppl.363 · DOI
- Osterman, 2020, Trends in initial systemic therapy for elderly patients with metastatic clear cell renal cell carcinoma., Kidney Cancer, 4, 131, 10.3233/KCA-200089 · doi:10.3233/kca-200089
- Strohbehn, 2021, Registration trials in countries without access to US standards of care—pitfalls of interpretation., Nat Rev Clin Oncol, 18, 395, 10.1038/s41571-021-00506-z · doi:10.1038/s41571-021-00506-z
Cited by
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04266-7
Metadata
- Authors
- Rose, T. L., & Kim, W. Y.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-09-24
- Volume
- 332
- Issue
- 12
- Pages
- 1001
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4401948805
- Cited by
- 374
- References
- 56
- FWCI
- 95.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.